1. Generics Bulletin
  2. >>Products

Mallinckrodt Underlines It Will Not Be A ‘Supermarket’ 12 Months After Bankruptcy

‘We Cannot Compete With Low-Cost India,’ Firm Says At It Welcomes Stability

 
• By Dean Rudge

Mallinckrodt has spoken about maintaining a steady organization, underpinned by few launches in the pain and neurodevelopmental disorders space.

Supermarket_shutterstock_418522381_620x413.jpg
Shutterstock

Mallinckrodt says it is “more than happy” to continue executing on only two or three generic controlled-substance launches per year in the US, as the firm looks to maintain and grow its operations 12 months after emerging from a second bankruptcy in quick succession.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Generics Bulletin

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

 
• By Dave Wallace

Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.

OGD’s Policy Office Cut To Have ‘Profound’ Impact On New Generic Approvals, Warns Former FDA Head Gottlieb

 
• By Urtė Fultinavičiūtė

The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.